Treace Medical Concepts, Inc. (TMCI) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 29, 2022, by Treace Medical Concepts, Inc. The filing details the entry into new material definitive financing agreements and the termination of prior debt facilities. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Debt Structure
The Company secured new financing through two primary agreements with entities affiliated with MidCap Financial Trust:
- Term Loan Facility: A 60-month facility with a total capacity of $120.0 million across four tranches.
- Initial Draw: $50.0 million drawn at closing.
- Remaining Capacity: Up to $70.0 million subject to revenue objectives.
- Interest Rate: Adjusted Term SOFR (floored at 1.00%, capped at 3.00%) plus 6.00%.
- Revolving Loan Facility: A 60-month facility with an initial capacity of $30.0 million.
- Expansion Option: Can be increased by $20.0 million to a total of $50.0 million.
- Initial Draw: $4.0 million drawn at closing.
- Interest Rate: Adjusted Term SOFR (floored at 1.00%, capped at 3.00%) plus 4.00%.
- Fees: 0.50% collateral management fee on outstanding balance; 0.50% unused line fee; 0.25% annual administrative fee on Term Loan.
- Repayment Terms: Interest-only payments for the first 48 months, followed by straight-line amortization for the remaining 12 months. An extension to 60 months of interest-only payments is possible if revenue objectives are met.
- Prepayment Penalties: 3.0% in year one, 2.0% in year two, and 1.0% in year three and thereafter. A final payment fee of 3.0% applies to the Term Loan.
- Collateral: Secured by substantially all Company assets, including intellectual property.
Material Changes vs. Prior Period
Concurrent with the new financing, the Company terminated its previous debt obligations:
- CRG Loan Agreement: The outstanding balance and fees totaling $30 million were paid in full, and the facility was terminated.
- SVB Loan Agreement: The Loan and Security Agreement with Silicon Valley Bank was terminated.
Guidance, Covenants, and Risks
Covenants: The Loan Agreements contain customary affirmative and negative covenants. A minimum trailing twelve-month revenue covenant applies only if the Company's liquidity (unrestricted cash plus undrawn revolving availability) falls below the outstanding Term Loan balance. If liquidity exceeds the Term Loan balance, no minimum revenue level is required.
Risks: Future borrowing capacity under the Term Loan is contingent upon achieving specific revenue objectives. Prepayment penalties may impact the Company's ability to refinance or repay debt early without significant cost.
Investor Verification Checklist
- Verify the specific revenue objectives required to unlock the remaining $70.0 million Term Loan tranche and the $20.0 million Revolver expansion.
- Confirm the current Adjusted Term SOFR rate to calculate the effective all-in interest cost.
- Review the Company's current liquidity position to determine if the revenue covenant is currently active.
- Assess the impact of the 3.0% final payment fee on the Term Loan on long-term capital planning.